Sigilon Therapeutics, Inc. SGTX
At closeAug 10, 2023, 4:00 PM EDT
- Market cap
- 56.22M
- Revenue (ttm)
- 14.64M
- Profit margin
- -253.33%
- EPS (ttm)
- -14.83
- Shares out
- 2.50M
- P/E ratio
- -1.52
- Forward P/E
- -1.66
- Volume
- 81.88K
- Avg volume
- 120.68K
- Open
- 22.90
- Previous close
- 22.47
- Day's range
- 22.09 – 23.08
- 52-week range
- 3.77 – 28.00
- Beta
- 4.17
- Analysts
- Buy
- Price target
- 47.33 (+110.6%)
- Earnings date
- Aug 7, 2023
Key statistics
- Enterprise value
- 23.24M
- PEG ratio
- 0.00
- Price / sales
- 3.66
- Price / book
- 1.61
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 53.50%
- Free cash flow
- -31.71M
- Total cash
- 56.37M
- Total debt
- 25.47M
- Return on equity
- -75.77%
- Short % of float
- 0.56%
- 50-day average
- 8.55
- 200-day average
- 8.23
Analyst view
Consensus: buy
- Target (low)
- 21.00
- Target (mean)
- 47.33
- Target (high)
- 91.00
- Strong buy2
- Buy1
- Hold1
- Sell0
- Strong sell0
Next earnings
Aug 7, 2023
Expected Aug 7, 2023. Consensus EPS estimate -4.71.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Aug 7, 2023 | Jun 1, 2023 | 0.00 | — | — | — |
| May 9, 2023 | Mar 1, 2023 | 0.00 | — | — | — |
| Mar 14, 2023 | Dec 1, 2022 | 0.00 | — | — | — |
| Nov 10, 2022 | Sep 1, 2022 | -5.59 | — | — | — |
| Aug 4, 2022 | Jun 1, 2022 | -5.98 | — | — | — |
| May 12, 2022 | Mar 1, 2022 | -3.90 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Jan 18, 2023 | Canaccord Genuity | init | — | Buy |
| Dec 23, 2021 | Canaccord Genuity | main | — | Buy |
| Dec 1, 2021 | Barclays | main | — | Overweight |
| Nov 30, 2021 | Morgan Stanley | main | — | Equal-Weight |
| Nov 30, 2021 | Jefferies | down | Buy | Hold |
| Oct 29, 2021 | BTIG | init | — | Buy |
About Sigilon Therapeutics, Inc.
Sigilon Therapeutics, Inc., a preclinical stage biotechnology company, develops functional cures for patients with acute and chronic diseases. Its lead product candidate is SIG-002 to replace islet cells for the treatment of type 1 diabetes; and SIG-001, which is in Phase I/II clinical trial to prevent bleeding episodes in patients with moderate to severe Hemophilia A. The company is also developing SIG-205, SIG-218, SIG-220, and SIG-005, which are to treat the non-neurological manifestations of mucopolysaccharidosis type 1; and SIG-207 is to treat of Fabry disease. Sigilon Therapeutics, Inc. has a research collaboration and license agreement with Eli Lilly and Company for the development and commercialization of SLTx product candidates for the treatment of Type 1 Diabetes. The company was formerly known as Sigilon, Inc. and changed its name to Sigilon Therapeutics, Inc. in June 2017. Sigilon Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- sigilon.com
News
Benzinga's Top Ratings Upgrades, Downgrades For June 30, 2023 
Earnings Scheduled For March 15, 2023 
Why Starbox Group Shares Are Trading Higher By 22%; Here Are 20 Stocks Moving Premarket 
Why Ontrak Shares Are Trading Higher By Over 100%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session 
US Stocks Turn Lower; Dow Dips Over 300 Points 
Stocks That Hit 52-Week Lows On Friday - Stocks That Hit 52-Week Lows On Thursday
- Stocks That Hit 52-Week Lows On Thursday
Stocks That Hit 52-Week Lows On Wednesday - Stocks That Hit 52-Week Lows On Friday
Your note
Sign in to keep a note on SGTX — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ANDERSON DANIEL GRIFFITH | Director | Sale | Jun 1, 2021 | 2,022,220 |
| COX JOHN | Director | Conversion of Exercise of derivative security | Dec 7, 2020 | 0 |
| ELI LILLY & CO | Beneficial Owner of more than 10% of a Class of Security | Purchase | Dec 7, 2020 | 2,744,440 |
| FLAGSHIP VENTURES FUND V GENERAL PARTNER L.L.C | Beneficial Owner of more than 10% of a Class of Security | Conversion of Exercise of derivative security | Dec 7, 2020 | 0 |
| PONTES JOSIAS | Officer | Stock Award(Grant) | Sep 29, 2021 | 13,339 |
| RUFFOLO ROBERT R JR | Director | Sale | Jun 30, 2021 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Flagship Pioneering Inc. | 2.45% | 797,720 | 17.08M | Mar 30, 2023 |
| Canada Pension Plan Investment Board | 0.35% | 114,245 | 2.45M | Mar 30, 2023 |
| FMR, LLC | 0.25% | 81,123 | 1.74M | Mar 30, 2023 |
| Blackrock Inc. | 0.25% | 80,706 | 1.73M | Mar 30, 2023 |
| Cercano Management LLC | 0.21% | 68,071 | 1.46M | Mar 30, 2023 |
| Harbourvest Partners, LLC | 0.18% | 56,980 | 1.22M | Mar 30, 2023 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| BlackRock Health Sciences Trust II | 1.74% | 564,538 | 12.09M | Dec 30, 2022 |
| Fidelity Growth Company Fund | 1.15% | 374,436 | 8.02M | Feb 27, 2023 |
| Blackrock Funds-Health Sciences Opportunity Portfolio | 1.02% | 332,626 | 7.12M | Feb 27, 2023 |
| Vanguard Total Stock Market Index Fund | 0.56% | 181,760 | 3.89M | Dec 30, 2022 |
| Bridgeway Funds Inc-Ultra Small Company Market Fund | 0.39% | 125,000 | 2.68M | Dec 30, 2022 |
| Fidelity Growth Company K6 Fund | 0.33% | 107,734 | 2.31M | Feb 27, 2023 |